  Type 2 diabetes (T2D) is closely linked with non-alcoholic fatty liver
disease (NAFLD) and hepatic insulin resistance, but the involved mechanisms are
still elusive. Using DNA methylome and transcriptome analyses of livers from
obese individuals, we found that both hypomethylation at a CpG site in PDGFA
(encoding platelet derived growth factor alpha) and PDGFA overexpression are
associated with increased T2D risk, hyperinsulinemia, increased insulin
resistance and increased steatohepatitis risk. Both genetic risk score studies
and human cell modeling pointed to a causative impact of high insulin levels on
PDGFA CpG site hypomethylation, PDGFA overexpression, and increased PDGF-AA
secretion from liver. We found that PDGF-AA secretion further stimulates its
own expression through protein kinase C activity and contributes to insulin
resistance through decreased expression of both insulin receptor substrate 1
and of insulin receptor. Importantly, hepatocyte insulin sensitivity can be
restored by PDGF-AA blocking antibodies, PDGF receptor inhibitors and by
metformin opening therapeutic avenues. Conclusion: Therefore, in the liver of
obese patients with T2D, the increased PDGF-AA signaling contributes to insulin
resistance, opening new therapeutic avenues against T2D and NAFLD.
